

Biotage AB changes in number of shares and votes

As previously announced, the shareholders resolved at the Annual General Meeting held on 26 April 2012 to withdraw 6,381,983 shares, which had been repurchased under the company's re-purchase program. Following withdrawal of these shares the number of outstanding shares and votes amounts to 73,255,705 as of 31 May 2012.

Contact:

Torben Jörgensen, President and CEO Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 9.00 on 5 June 2012.

About Biotage

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has 270 employees and had sales of 428.4 MSEK in 2011. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com